--- title: "Abeona Therap | 8-K: FY2026 Q2 Revenue: USD 11.38 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295790797.md" datetime: "2026-08-13T11:32:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295790797.md) - [en](https://longbridge.com/en/news/295790797.md) - [zh-HK](https://longbridge.com/zh-HK/news/295790797.md) --- # Abeona Therap | 8-K: FY2026 Q2 Revenue: USD 11.38 M Revenue: As of FY2026 Q2, the actual value is USD 11.38 M. EPS: As of FY2026 Q2, the actual value is USD -0.35. EBIT: As of FY2026 Q2, the actual value is USD -12.99 M. ### Segment Revenue Net ZEVASKYN revenue for the second quarter of 2026 increased 31% quarter-over-quarter to $11.4 million, compared to $8.7 million in the first quarter of 2026. Product revenue, net, was $11,380 thousand for the three months ended June 30, 2026, up from $0 thousand for the same period in 2025. Total revenues for the second quarter of 2026 were $11,380 thousand, compared to $400 thousand in the second quarter of 2025. For the six months ended June 30, 2026, total revenues were $20,100 thousand, compared to $400 thousand for the six months ended June 30, 2025. ### Operational Metrics #### Net Loss For the second quarter of 2026, Abeona Therapeutics Inc. reported a net loss of - $20.2 million, or - $0.35 per basic and diluted common share, compared to a net loss of - $17.1 million, or - $0.30 per basic and diluted common share, in the first quarter of 2026. The net loss was - $20,191 thousand for the three months ended June 30, 2026, compared to a net income of $108,833 thousand for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $37,266 thousand, compared to a net income of $96,804 thousand for the six months ended June 30, 2025. #### Loss from Operations Loss from operations for the three months ended June 30, 2026, was - $13,653 thousand, an improvement from - $22,792 thousand for the same period in 2025. For the six months ended June 30, 2026, the loss from operations was - $36,686 thousand, compared to - $42,519 thousand for the six months ended June 30, 2025. #### Research and Development (R&D) Expenses R&D expenses were $5.0 million for the second quarter of 2026, a decrease from $9.6 million in the first quarter of 2026, which included a one-time, up-front cost of $7.0 million for in-licensing ABO-701. For the three months ended June 30, 2026, R&D expenses were $5,021 thousand, compared to $5,943 thousand for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $14,576 thousand, compared to $15,884 thousand for the six months ended June 30, 2025. #### Selling, General and Administrative (SG&A) Expenses SG&A expenses were $15.8 million for the second quarter of 2026, down from $19.5 million for the first quarter of 2026, primarily due to fewer engineering runs and less manufacturing training costs. For the three months ended June 30, 2026, SG&A expenses were $15,835 thousand, compared to $17,149 thousand for the same period in 2025. For the six months ended June 30, 2026, SG&A expenses were $35,337 thousand, compared to $26,935 thousand for the six months ended June 30, 2025. #### Cost of Sales Cost of sales for the three months ended June 30, 2026, was $4,177 thousand, compared to $0 thousand for the same period in 2025. For the six months ended June 30, 2026, cost of sales was $6,873 thousand, compared to $0 thousand for the six months ended June 30, 2025. #### Other Financial Items (Three Months Ended June 30, 2026 vs. 2025) - Interest income: $1,355 thousand (2026) vs. $1,027 thousand (2025). - Interest expense: - $696 thousand (2026) vs. - $957 thousand (2025). - Change in fair value of warrant liabilities: - $7,191 thousand (2026) vs. - $5,388 thousand (2025). - Gain from sale of priority review voucher, net: $0 thousand (2026) vs. $152,366 thousand (2025). - Income tax expense: $0 thousand (2026) vs. $15,512 thousand (2025). ### Cash and Investments Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, down from $191.4 million as of December 31, 2025. ### Unique Operational Metrics #### ZEVASKYN Treatments Five patients were treated with ZEVASKYN in the second quarter of 2026, and three treatments have been completed in the third quarter of 2026 to-date. Since launch, a total of 12 patient treatments have been completed. Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications. #### Qualified Treatment Center (QTC) Network Expansion NewYork-Presbyterian/Columbia University Irving Medical Center and Children’s Hospital of Philadelphia (CHOP) were activated as QTCs during the second quarter of 2026. CHOP and University of Texas Medical Branch (UTMB) have started collecting patient biopsies, and CHOP has treated its first patient with ZEVASKYN. Cincinnati Children’s was activated as the newest ZEVASKYN QTC in the third quarter of 2026. #### CMS NTAP Status Effective October 1, 2026, ZEVASKYN will have New Technology Add-On Payment (NTAP) status under the fiscal year 2027 Hospital Inpatient Prospective Payment System Final Rule from CMS. This status provides a pathway for eligible hospitals to receive supplemental payments from CMS for treating Medicare beneficiaries with ZEVASKYN. ### Outlook Abeona Therapeutics Inc.’s CEO, Vish Seshadri, expressed reinforced confidence in ZEVASKYN’s substantial opportunity due to launch progress and experience. The company anticipates driving broader adoption and long-term growth as real-world experience with ZEVASKYN matures across activated sites. ### Related Stocks - [ABEO.US](https://longbridge.com/en/quote/ABEO.US.md) ## Related News & Research - [Abeona Therapeutics grants 10,800 restricted shares to new hires under Nasdaq inducement rule](https://longbridge.com/en/news/294685938.md) - [Abeona Therapeutics Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295818848.md) - [Abeona Therapeutics Q2 net loss widens, misses analyst expectations](https://longbridge.com/en/news/295791975.md) - ['American Pie' star Seann William Scott lists stunning Malibu waterfront home for $17.5 million](https://longbridge.com/en/news/295908342.md) - [Oil rises further as Hormuz talks show little progress](https://longbridge.com/en/news/295501528.md)